NINLARO is an oral approach to proteasome inhibition, designed to deliver sustained efficacy in RRMM1,2
NINLARO is the first and only oral PI licensed in combination with Rd for the treatment of adult patients with MM who have received at least 1 prior therapy1
Adding oral NINLARO to Rd:
Achieves rapid responses and significantly extends PFS across a broad group of patients irrespective of cytogenetic risk, compared with Rd alone2
Is generally well-tolerated with manageable side effects2
Offers the convenience of an all-oral regimen with minimal additional burden on patients and the health system1,2
Oral NINLARO was studied in a broad group of RRMM patients who were treated to progression2
TOURMALINE‑MM1 is the first global, phase III, double‑blind, placebo‑controlled study investigating an oral PI in RRMM patients. The trial compared NINLARO + Rd as part of an all oral regimen versus placebo + Rd in 722 RRMM patients treated with 1-3 prior therapies2
Takeda Oncology has developed a range of information and support tools designed for patients prescribed NINLARO
- NINLARO (ixazomib capsules) Summary of Product Characteristics.
- Moreau P, Masszi T, Grzasko N. N Engl J Med. 2016;374:1621-34.